GINA 2021哮喘管理策略:执行摘要与关键变更依据
本文总结GINA 2021的关键推荐及支持近期变更的证据。GINA建议成人及青少年哮喘不应单用短效β2受体激动剂(SABA),因单用SABA及过度使用存在风险,且有吸入糖皮质激素(ICS)获益证据。大型试验显示按需ICS-福莫特罗较单用SABA减少轻度哮喘严重急性发作≥60%。
要点
- 成人及青少年哮喘不应单用SABA治疗。
- 轻度哮喘按需ICS-福莫特罗较单用SABA减少严重急性发作≥60%。
- GINA 2021治疗图分两轨:首选轨以ICS-福莫特罗为缓解剂。
核心结论
- GINA建议成人及青少年哮喘不应单用SABA治疗,因单用SABA及过度使用存在风险且有ICS获益证据。
- 大型试验显示按需ICS-福莫特罗较单用SABA在轻度哮喘中减少严重急性发作≥60%,且症状、肺功能及炎症结局与每日ICS加按需SABA相似。
研究设计与样本
- 本文为GINA 2021策略报告执行摘要,总结关键推荐及支持近期变更的证据。
主要发现
- GINA 2021将成人和青少年治疗图分为两轨:首选轨以低剂量ICS-福莫特罗为缓解剂,第1-2步按需使用,第3-5步为维持加缓解治疗(MART)。
- 替代轨全程按需SABA,加规律ICS(第2步)或ICS-长效β2受体激动剂(第3-5步)。
- 对中重度哮喘成人,第5步额外推荐加用长效毒蕈碱拮抗剂和阿奇霉素,重症哮喘加用生物制剂。
- 6-11岁儿童在第3-4步新增治疗选择。
关键数值与推荐
- 大型试验显示按需ICS-福莫特罗较单用SABA减少轻度哮喘严重急性发作≥60%。
- 首选轨第1-2步按需使用低剂量ICS-福莫特罗,第3-5步使用维持加缓解治疗(MART)。
- 替代轨全程按需SABA,第2步加规律ICS,第3-5步加ICS-长效β2受体激动剂。
- 中重度哮喘成人第5步可加用长效毒蕈碱拮抗剂和阿奇霉素,重症哮喘加用生物制剂。
临床怎么用
- 成人及青少年哮喘不应单用SABA,应优先选择含ICS的方案。
- 轻度哮喘可按需使用低剂量ICS-福莫特罗作为缓解剂。
- 中重度哮喘按GINA 2021分轨选择维持及缓解治疗,第5步考虑附加治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The GINA Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention. This article summarizes key recommendations from GINA 2021, and the evidence underpinning the new changes. https://bit.ly/3FZblIS The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g. medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting β2-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS–formoterol reduces severe exacerbations by ≥60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS–formoterol as the reliever at all steps: as needed only in Steps 1–2 (mild asthma), and with daily maintenance ICS–formoterol (maintenance-and-reliever therapy, “MART”) in Steps 3–5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS–long-acting β2-agonist (Steps 3–5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6–11 years, new treatment options are added at Steps 3–4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.
引用
- Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2021. PMID: 34667060. doi:10.1183/13993003.02730-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。